Cyclophosphamide and Uvadex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cyclophosphamide (cyclophosphamide) and Uvadex (methoxsalen). Common drug interactions include vascular access complication among females and chronic graft versus host disease among males.

The phase IV clinical study analyzes what interactions people have when they take Cyclophosphamide and Uvadex. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Cyclophosphamide?

Cyclophosphamide has active ingredients of cyclophosphamide. It is often used in multiple myeloma. eHealthMe is studying from 185,240 Cyclophosphamide users. Check the latest studies of Cyclophosphamide.

What is Uvadex?

Uvadex has active ingredients of methoxsalen. eHealthMe is studying from 597 Uvadex users. Check the latest studies of Uvadex.

On Jul, 08, 2026

14 people who take Cyclophosphamide and Uvadex together, and have interactions are studied.

Cyclophosphamide and Uvadex drug interactions.

What are the common drug interactions of Cyclophosphamide and Uvadex, by gender? *:

female:

Vascular access complication
Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Disease progression
Dizziness
Fatigue (feeling of tiredness)
Toxoplasmosis (a parasitic disease caused by the protozoan toxoplasma gondii)

male:

Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Disease progression
Cerebral toxoplasmosis (parasitic disease of brain caused by the protozoan toxoplasma gondii)
Fatigue (feeling of tiredness)
Vascular access complication
Respiratory tract infection
Cytomegalovirus infection
Haematuria (presence of blood in urine)
Hyperglycaemia (high blood sugar)
Hypertension (high blood pressure)

What are the common drug interactions of Cyclophosphamide and Uvadex, by age (0-1 to 60+)? *:

0-1:

Vascular access complication

2-9:

Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Disease progression
Vascular access complication
Dizziness
Fatigue (feeling of tiredness)

10-19:

Kaposi's sarcoma (a tumour caused by human herpes virus)
Pyrexia (fever)
Cerebral toxoplasmosis (parasitic disease of brain caused by the protozoan toxoplasma gondii)
Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Disease progression
Fatigue (feeling of tiredness)
Respiratory tract infection
Toxoplasmosis (a parasitic disease caused by the protozoan toxoplasma gondii)
Vascular access complication
Cytomegalovirus infection

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 10 people, 71.43%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 8 people, 57.14%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 4 people, 28.57%
Graft Versus Host Disease In Skin (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the skin): 1 person, 7.14%
Acute Graft Versus Host Disease In Skin (acute complication on skin following an allogeneic tissue/blood transplant): 1 person, 7.14%
Acute Graft Versus Host Disease In Liver (acute complication in liver following an allogeneic tissue/blood transplant): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Cyclophosphamide and Uvadex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously